

SPARKLE ASSETS LIMITED
(the “**Company**”)
(Incorporated in the British Virgin Islands with limited liability)

ANNOUNCEMENT

We refer to the US\$400,000,000 6.875% Senior Notes due 2020 issued by the Company on 30 January 2013 and guaranteed by, *inter alias*, Fosun International Limited (the “**Parent Guarantor**”).

The Parent Guarantor has released the attached announcement dated 24 April 2017 on The Stock Exchange of Hong Kong Limited.

BY ORDER OF THE BOARD

Qin Xuetang
Director

24 April 2017

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUNPHARMA
复星医药

上海復星醫藥(集團)股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
*(a joint stock limited company incorporated in the People's Republic of
China with limited liability)*
(Stock Code: 02196)

FOSUN 复星

復星國際有限公司
FOSUN INTERNATIONAL LIMITED
(Incorporated in Hong Kong with limited liability)
(Stock Code: 00656)

JOINT ANNOUNCEMENT

DISCLOSEABLE TRANSACTION — PROGRESS ON ACQUISITION OF THE CONTROLLING INTEREST IN GLAND PHARMA LIMITED

Reference is made to the joint announcement dated 28 July 2016 of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“**Fosun Pharma**”) and Fosun International Limited (“**Fosun International**”), the controlling shareholder of Fosun Pharma, the announcements of Fosun Pharma dated 4 August 2016 and 30 March 2017 and the circular of Fosun Pharma dated 11 August 2016 (the “**Circular**”) and the poll results announcement of Fosun Pharma dated 29 September 2016 in connection with, among other things, acquiring approximately 86.08% equity interest in Gland Pharma Limited. Unless otherwise specified, capitalized terms used herein shall have the same meaning ascribed to them in the Circular.

PROGRESS ON THE ACQUISITION

Under the Share Purchase Agreement, in the event that not all of the conditions precedent to the SPA Closing have been fulfilled upon the Termination Date, parties to the Share Purchase Agreement shall have the right to terminate the Share Purchase Agreement. However, in the event that all the conditions precedent, other than the approval by the competent antitrust authorities of India, competent foreign investment authorities of India and the competent antitrust authorities of the United States and the NDRC in relation to foreign investment, have been fulfilled, then the Termination Date shall be extended to 27 April 2017.

As at the date of this announcement, the relevant approvals of competent authorities of the PRC in relation to the Acquisition have been obtained, and filings with the competent antitrust authorities of the United States and India have been completed. In addition, the Acquisition was reviewed by the Indian Foreign Investment Promotion Board (“**FIPB**”) and will be recommended to the Cabinet Committee on Economic Affairs of India for further review and approval. Accordingly, the Termination Date was automatically extended to 27 April 2017 in accordance with the Share Purchase Agreement.

For the purpose of moving forward with the Acquisition, on 24 April 2017, Fosun Pharma, the Buyer, KKR, the Founder Shareholders and the Target Company entered into the Amendment No. 1 to the Share Purchase Agreement (the “**Amendment No. 1**”), pursuant to which the parties agreed to further extend Termination Date to 27 July 2017. Except for the extension of the Termination Date provided in the Amendment No.1, all terms of the Share Purchase Agreement shall remain in full force and effect without amendment, modification or supplement. The Amendment No. 1 shall form an integral part of the Share Purchase Agreement.

Shareholders and potential investors of Fosun Pharma and Fosun International should note that pending the obtaining of approval from FIPB, the Acquisition may or may not proceed. Shareholders and potential investors of Fosun Pharma and Fosun International are reminded to exercise caution when dealing in the securities of each of Fosun Pharma and Fosun International.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
Chairman

By order of the board
Fosun International Limited
Guo Guangchang
Chairman

24 April 2017

As at the date of this announcement, the executive directors of Fosun Pharma are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors of Fosun Pharma are Mr. Guo Guangchang, Mr. Wang Qunbin, Ms. Kang Lan and Mr. Wang Can; and the independent non-executive directors of Fosun Pharma are Mr. Cao Huimin, Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin and Mr. Wai Shiu Kwan Danny.

As at the date of this announcement, the executive directors of Fosun International are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Chen Qiyu, Mr. Xu Xiaoliang, Mr. Qin Xuetao, Mr. Wang Can, Ms. Kang Lan and Mr. Gong Ping; and the independent non-executive directors of Fosun International are Mr. Zhang Shengman, Mr. Zhang Huaqiao, Mr. David T. Zhang, Mr. Yang Chao and Dr. Lee Kai-Fu.

* for identification purposes only